» Articles » PMID: 37890055

Tobacco Cessation Following Laryngeal Cancer Diagnosis Predicts Response to Treatment and Laryngectomy-Free Survival

Overview
Publisher Wiley
Date 2023 Oct 27
PMID 37890055
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the effect of tobacco cessation following laryngeal cancer diagnosis on response to first-line therapy, laryngectomy-free survival, and overall survival in patients who were current smokers at the time of diagnosis.

Study Design: Retrospective, case-control study.

Setting: OU Stephenson Cancer Center, National Cancer Institute-Designated Cancer Center.

Methods: We included 140 patients diagnosed with laryngeal squamous cell carcinoma, who were current smokers at the time of diagnosis, and were treated with first-line definitive radiation or chemo/radiation with the intent to cure. The association between patient characteristics and treatment response was assessed using the χ test and logistic regression analysis. Survival outcomes were analyzed using Kaplan-Meier methods and Cox proportional-hazards models.

Results: Of the 140 current smokers, 61 patients (45%) quit smoking prior to treatment initiation. In adjusted logistic regression analysis, quitters had 3.7 times higher odds of achieving a complete response to first-line therapy than active smokers (odds ratio: 3.694 [1.575-8.661]; P = .003). In the adjusted Cox proportional-hazards model, quitters were 54% less likely to require salvage laryngectomy within 7 years of diagnosis than active smokers (hazard ratio: 0.456 [0.246-0.848]; P = .013). Quitters had a statistically significant increase in 7-year overall survival compared to active smokers (P = .02).

Conclusion: This is the first study to show that in newly diagnosed laryngeal cancer patients who are current smokers at the time of diagnosis, tobacco cessation significantly increases therapy response, laryngectomy-free survival, and overall survival. These data stress the importance of systematically incorporating tobacco cessation programs into laryngeal cancer treatment plans.

Citing Articles

Exposure to Secondhand Smoke Extract Increases Cisplatin Resistance in Head and Neck Cancer Cells.

Sadhasivam B, Manyanga J, Ganapathy V, Acharya P, Bouharati C, Chinnaiyan M Int J Mol Sci. 2024; 25(2).

PMID: 38256106 PMC: 10816441. DOI: 10.3390/ijms25021032.

References
1.
Choi S, Terrell J, Bradford C, Ghanem T, Spector M, Wolf G . Does Quitting Smoking Make a Difference Among Newly Diagnosed Head and Neck Cancer Patients?. Nicotine Tob Res. 2016; 18(12):2216-2224. PMC: 5103939. DOI: 10.1093/ntr/ntw189. View

2.
Kalyankrishna S, Grandis J . Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006; 24(17):2666-72. DOI: 10.1200/JCO.2005.04.8306. View

3.
Patnode C, Henderson J, Coppola E, Melnikow J, Durbin S, Thomas R . Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021; 325(3):280-298. DOI: 10.1001/jama.2020.23541. View

4.
Caini S, Riccio M, Vettori V, DEcclesiis O, Bonomo P, Locatello L . Post-diagnosis smoking cessation and survival of patients with head and neck cancer: a systematic review and meta-analysis. Br J Cancer. 2022; 127(11):1907-1915. PMC: 9681856. DOI: 10.1038/s41416-022-01945-w. View

5.
Kahler C, Borland R, Hyland A, McKee S, Thompson M, Cummings K . Alcohol consumption and quitting smoking in the International Tobacco Control (ITC) Four Country Survey. Drug Alcohol Depend. 2008; 100(3):214-20. PMC: 2649759. DOI: 10.1016/j.drugalcdep.2008.10.006. View